Insmed(INSM)
Focus: Insmed is a public biotechnology company focused on inhalable liposomal therapeutics across neurology, rare diseases, cardiovascular, respiratory, and ophthalmology. The company operates at mid-cap scale with ~1-50 employees and commercializes approved respiratory and rare disease treatments.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
91-2 this month
Stable — net -2 jobs in 30d
49 added, 51 removed. Backfill posture.
Should You Work at Insmed?
AI assessmentInsmed is a high-growth, R&D-intensive rare respiratory biotech with credible near-term pipeline catalysts and commercial traction, suited for candidates seeking early-stage impact in a scaling organization willing to accept burn-rate volatility.
Why Work Here
- Strong commercial momentum: FY2025 revenue grew 24.5% YoY to $305M, signaling successful market execution of approved therapies.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$305M
Key Products
Peak8.6yr
Approved inhalable liposomal amikacin for CF-related infections; patent protected through 2035.
Help build intelligence for Insmed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.